Posted in Research News on Feb 28th, 2011
Matthew Callaghan, MD, had an epiphany about medical device design during a planning meeting, when his hospital was drafting a worst-case scenario protocol to decide which types of patients would receive life support from the hospital’s limited number of breathing ventilators. “The physicians assumed that we’d have to ration the ventilators, and that if we [...]
Posted in speakers on Mar 18th, 2010
The United States’ commitment to comparative effectiveness research for medical treatments could hamper young companies and delay some products, but also it could create more value for successful early-stage companies, agreed speakers at a roundtable on biodesign held at the Stanford Graduate School of Business. http://www.gsb.stanford.edu/news/headlines/biodesign_2_10.html Share, Email or Print:
Posted in Research News on Mar 17th, 2010
The United States’ commitment to comparative effectiveness research for medical treatments could hamper young companies and delay some products, but it also could create more value for successful early-stage companies, agreed speakers at a roundtable on biodesign held at the Stanford Graduate School of Business. In 2009, the government began the work of reforming America’s [...]
